MedTrace Logo

Investigation of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty

NCT02569658 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2021-11-02

Study results available
· View outcomes & findings →

Summary

To compare intravenous Tranexamic Acid (TXA) versus normal saline placebo to determine whether or not TXA administration reduces blood loss, decrease in hemoglobin, and rate of transfusions following anatomic and reverse total shoulder arthroplasty (TSA) surgeries.

Conditions

  • Blood Loss
  • Anatomic Total Shoulder Arthroplasty
  • Reverse Total Shoulder Arthroplasty
  • Transfusion
  • Tranexamic Acid

Interventions

DRUG

Tranexamic Acid

DRUG

Placebo

Sponsors & Collaborators

  • Rush University Medical Center

    lead OTHER

Principal Investigators

  • Gregory Cvetanovich, MD · Rush University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02569658 on ClinicalTrials.gov